ISSN:
2352-3026
Disciplines
(Field of Science):
- biomedical engineering (Engineering and Technology)
- medical biology (Medical and Health Sciences )
- pharmacology and pharmacy (Medical and Health Sciences )
- medical sciences (Medical and Health Sciences )
- health sciences (Medical and Health Sciences )
- biotechnology (Natural sciences)
- biological sciences (Natural sciences)
(Field of Science)
Ministry points: Help
Year | Points | List |
---|---|---|
Year 2024 | 200 | Ministry scored journals list 2024 |
Year | Points | List |
---|---|---|
2024 | 200 | Ministry scored journals list 2024 |
2023 | 200 | Ministry Scored Journals List |
2022 | 200 | Ministry Scored Journals List 2019-2022 |
2021 | 200 | Ministry Scored Journals List 2019-2022 |
2020 | 200 | Ministry Scored Journals List 2019-2022 |
2019 | 200 | Ministry Scored Journals List 2019-2022 |
2018 | 35 | A |
2017 | 35 | A |
2016 | 35 | A |
Model:
Hybrid
Points CiteScore:
Year | Points |
---|---|
Year 2023 | 26 |
Year | Points |
---|---|
2023 | 26 |
2022 | 25.5 |
2021 | 19.9 |
2020 | 17.3 |
2019 | 19.4 |
2018 | 18.2 |
2017 | 12.9 |
2016 | 6.8 |
2015 | 2.9 |
2014 | 1 |
Impact Factor:
Log in to see the Impact Factor.
Sherpa Romeo:
Papers published in journal
Filters
total: 3
Catalog Journals
Year 2017
-
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
Publication -
Research on Biosimilars: pivotal trials and principles
Publication -
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
Publication
seen 402 times